OncoPep is developing PVX-410, an investigational cancer vaccine designed to stop disease progression in multiple myeloma. In addition to smoldering multiple myeloma (SMM), our investigational peptide portfolio more broadly targets multiple myeloma, triple negative breast cancer (TNBC) and several solid cancer tumors (breast, colon, pancreatic, prostate).
OncoPep is dedicated to developing transformative targeted immunotherapeutics to prevent the progression of cancer and maintain quality of life for cancer patients. Our initial clinical focus is to halt disease progression in SMM and TNBC.
We are assembling a pipeline of investigational cancer vaccines to arm the patients' immune system to attack cancer. Our lead investigational vaccine, PVX-410, is positioned to enter Phase 2 clinical trials in SMM. PVX-410 has been investigated as a stand-alone therapy and in combination with immunomodulatory agents.
PVX-410 is being tested in investigator sponsored clinical trials to evaluate its potential to be an important component in future immune-therapy regimens for the treatment of cancer. OncoPep is advancing the development of PVX-410 for the treatment of patients with SMM and TNBC.